Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus - Trial NCT06400537
Access comprehensive clinical trial information for NCT06400537 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wuhan Union Hospital, China and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wuhan Union Hospital, China
Timeline & Enrollment
Phase 1
May 01, 2024
May 01, 2026
Primary Outcome
Safety and tolerability
Summary
The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double
 antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06400537
Non-Device Trial